Current Rating and Its Significance
MarketsMOJO’s 'Hold' rating for Glenmark Pharmaceuticals Ltd. indicates a balanced stance on the stock, suggesting that investors should maintain their existing positions rather than aggressively buying or selling. This rating reflects a comprehensive evaluation of the company’s quality, valuation, financial trend, and technical indicators. The rating was adjusted on 15 September 2026, with the Mojo Score declining from 72 to 65, signalling a more cautious outlook compared to the previous 'Buy' grade.
Here’s How Glenmark Looks Today
As of 19 September 2026, Glenmark Pharmaceuticals is classified as a midcap company operating within the Pharmaceuticals & Biotechnology sector. The stock has experienced a modest decline of 1.43% on the day, reflecting some short-term volatility. Over longer periods, the stock has delivered positive returns: 3.11% over the past month, 10.48% over three months, and a notable 16.90% year-to-date. The one-year return stands at 12.80%, demonstrating resilience amid sector fluctuations.
Quality Assessment
The company’s quality grade is rated as 'good', underpinned by strong operational metrics and financial discipline. Glenmark maintains a low Debt to EBITDA ratio of 0.13 times, highlighting its robust ability to service debt and manage leverage prudently. This low leverage reduces financial risk and provides flexibility for future investments or navigating market uncertainties. Additionally, the company’s Return on Equity (ROE) is an attractive 26.9%, signalling efficient utilisation of shareholder capital to generate profits.
Valuation Perspective
Glenmark’s valuation is currently deemed 'attractive'. The stock trades at a Price to Book Value of 6.4, which, while elevated, is considered reasonable relative to its peers and historical averages. The company’s PEG ratio stands at a low 0.1, indicating that the stock’s price growth is not excessively high compared to its earnings growth. This suggests that investors are paying a fair price for the company’s earnings potential, especially given the significant profit growth observed over the past year.
Financial Trend Analysis
The financial trend for Glenmark is characterised as 'flat', reflecting some recent challenges in quarterly performance. The latest quarterly results ending June 2026 show a decline in profitability compared to the previous four-quarter average. Profit Before Tax (PBT) excluding other income fell by 39.0% to ₹577.63 crores, while Profit After Tax (PAT) declined by 31.6% to ₹482.92 crores. Interest expenses increased by 26.76% to ₹54.00 crores, which may have exerted pressure on net margins. Despite these short-term headwinds, the company’s profits have risen by an impressive 177.5% over the past year, indicating strong underlying growth momentum.
Technical Outlook
The technical grade for Glenmark is 'mildly bullish'. The stock’s price movements over recent months show a positive trend, supported by consistent returns and relative strength compared to broader indices. Institutional investors hold a significant 39.54% stake in the company, reflecting confidence from sophisticated market participants who typically conduct thorough fundamental analysis. This institutional backing often provides stability and can be a positive signal for retail investors.
Comparative Performance and Market Position
Glenmark Pharmaceuticals has outperformed the BSE500 index in each of the last three annual periods, underscoring its competitive positioning within the midcap pharmaceutical space. The company is also ranked among the top 1% of all 4,000 stocks rated by MarketsMOJO, highlighting its strong overall standing. This performance consistency, combined with attractive valuation and solid quality metrics, supports the current 'Hold' rating as a prudent approach for investors seeking steady exposure without excessive risk.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
What This Rating Means for Investors
For investors, the 'Hold' rating on Glenmark Pharmaceuticals suggests maintaining current holdings while monitoring the company’s financial developments closely. The rating reflects a balance between the company’s strong quality and valuation attributes and the recent flat financial trend. Investors should consider the stock as a stable component of a diversified portfolio, particularly given its consistent returns and institutional support. However, the recent quarterly profit decline and rising interest costs warrant caution and close observation of upcoming earnings reports.
Outlook and Considerations
Looking ahead, Glenmark’s ability to sustain profit growth and improve quarterly results will be key to shifting the rating towards a more positive outlook. The pharmaceutical sector remains competitive and subject to regulatory and market dynamics, which can impact earnings visibility. Nonetheless, Glenmark’s strong balance sheet, attractive valuation, and solid technical positioning provide a foundation for potential upside if operational performance stabilises and improves.
Summary
In summary, Glenmark Pharmaceuticals Ltd. is currently rated 'Hold' by MarketsMOJO as of 15 September 2026, with the latest analysis reflecting data as of 19 September 2026. The company exhibits good quality, attractive valuation, a flat financial trend, and mildly bullish technicals. Investors are advised to maintain their positions while keeping a watchful eye on the company’s upcoming financial results and sector developments.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
